Citius Oncology (CTOR) Tax Provisions (2023 - 2026)

Citius Oncology (CTOR) has reported Tax Provisions for 4 consecutive years, with -$107347.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Tax Provisions fell 140.62% year-over-year to -$107347.0 in Q2 2026; TTM through Jun 2026 was $189923.0, a 84.49% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, up 83.5% from the prior year.
• Tax Provisions was -$107347.0 for Q2 2026 at Citius Oncology, up from -$231210.0 in the prior quarter.
• Over five years, Tax Provisions peaked at $432000.0 in Q2 2024 and troughed at -$231210.0 in Q1 2026.
• A 4-year average of $184664.3 and a median of $264240.0 in 2024 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions soared 83.5% in 2024 and slumped 187.5% in 2026, its largest moves.
• Over 4 years, Tax Provisions stood at $144000.0 in 2023, then soared by 83.5% to $264240.0 in 2024, then changed by 0.0% to $264240.0 in 2025, then slumped by 140.62% to -$107347.0 in 2026.
• The last three Tax Provisions figures came in at -$107347.0 (Q2 2026), -$231210.0 (Q1 2026), and $264240.0 (Q4 2025), per Business Quant data.